Redwood City, Calif. — October 3, 2025 — Leads & Copy — Coherus Oncology, Inc. (NASDAQ: CHRS) will present a poster at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 5-9, 2025, in National Harbor, Maryland.
The poster presentation will feature Abstract # 640: CHS-114, an anti-CCR8 cytolytic monoclonal antibody, which demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors. The presentation is scheduled for Saturday, November 8, 2025, at the Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
CHS-114 will also be highlighted in the Targets for Cancer IO: A Deep Dive live webinar series, specifically Webinar 6, focusing on the development of Anti-CCR8 Ab – Mechanisms and Clinical Results. This webinar will discuss the therapeutic target C-C chemokine receptor 8 (CCR8), its role in regulatory T cell (Treg) activity and immunosuppression, and advances in developing monoclonal antibodies for treating various cancers. The webinar is scheduled for October 22, 2025, from 12:00 – 2:00 pm Eastern Time and will be moderated by Enrico Lugli, PhD, Humanitas Research Hospital and Rahul Roychoudhuri, MD, PhD, University of Cambridge, with faculty members including Rosh Dias, MD, MRCP, Coherus Oncology; Varun Kapoor, PhD, Coherus Oncology; and Jo Van Ginderachter, PhD, Vrije Universiteit Brussel. Registration details can be found on SITC’s website.
Coherus Oncology is a commercial-stage innovative oncology company with LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor. The company focuses on expanding LOQTORZI’s applications and advancing its pipeline of antibody immunotherapy candidates, including Casdozokitug, a novel IL-27 antagonistic antibody, and CHS-114, a cytolytic anti-CCR8 antibody.
For Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com
Source: Coherus Oncology
